glycyl-arginyl-glycyl-aspartyl-serine has been researched along with betadex in 1 studies
| Studies (glycyl-arginyl-glycyl-aspartyl-serine) | Trials (glycyl-arginyl-glycyl-aspartyl-serine) | Recent Studies (post-2010) (glycyl-arginyl-glycyl-aspartyl-serine) | Studies (betadex) | Trials (betadex) | Recent Studies (post-2010) (betadex) |
|---|---|---|---|---|---|
| 190 | 0 | 42 | 8,785 | 97 | 4,452 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, H; Chen, J; Jiang, B; Kuang, Y; Li, C; Liao, T; Liu, C; Ren, J; Sun, Z | 1 |
1 other study(ies) available for glycyl-arginyl-glycyl-aspartyl-serine and betadex
| Article | Year |
|---|---|
A chitosan/mesoporous silica nanoparticle-based anticancer drug delivery system with a "tumor-triggered targeting" property.
Topics: Adamantane; Animals; Antibiotics, Antineoplastic; Benzimidazoles; beta-Cyclodextrins; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Chitosan; Delayed-Action Preparations; Doxorubicin; Drug Carriers; Drug Compounding; Female; Hydrogen-Ion Concentration; Mice; Mice, Inbred BALB C; Nanoparticles; Oligopeptides; Polyethylene Glycols; Porosity; Silicates; Tumor Burden | 2021 |